In the CONSORTIUM Study, a Phase 2 trial in patients at high risk of recurrent Clostridioides difficile infection (CDI), VE303 met its primary efficacy endpoint of preventing CDI recurrence at eight weeks. Overall, VE303 was observed to be generally well-tolerated in the trial. A Phase 3 trial of VE303 is planned to initiate in 2022.

About CONSORTIUM

Consortium Logo

CONSORTIUM (NCT03788434) was a randomized, double-blind Phase 2 study that evaluated safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) and efficacy of VE303 in patients at high risk for recurrence of CDI after completing a course of antibiotics for a prior CDI episode. VE303 met its primary endpoint of preventing CDI recurrence at eight weeks. Overall, VE303 was observed to be generally well-tolerated in the trial.

For additional study information, please visit Clinicaltrials.gov:

https://www.clinicaltrials.gov/ct2/show/NCT03788434